COVID-19 standard of care | GileadPro

VEKLURY is conditionally recommended in several major guidelines, including NIH, NICE, IDSA, MHLW and DGI, for appropriate patients hospitalised with COVID-191–6

Australian guidelines for the clinical care of people with COVID-19 (conditional recommendations)6
Consider using VEKLURY for adults hospitalised with moderate-to-severe COVID-19 who require oxygen but do not require noninvasive or invasive ventilation:

VEKLURY probably reduces the risk of death in adult patients who do not require NIV, IMV or ECMO.

VEKLURY is NOT recommended for adults hospitalised with COVID-19 who require ventilation:

Use of VEKLURY may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include VEKLURY.

Consider using VEKLURY within 7 days of symptom onset in unvaccinated* adults with COVID-19 who do not require oxygen and who have one or more risk factors for disease progression:

VEKLURY probably reduces the risk of hospitalisation if taken within 7 days on onset of symptoms

Consider using VEKLURY within 7 days of symptom onset in adults with COVID-19 who do not require oxygen and are immunocompromised regardless of vaccination status; or who are not up-to-date with vaccination and who are at high risk of severe disease on the basis of age and multiple risk factors.
Medical practitioners can access VEKLURY through the National Medical Stockpile via their local health department.

▼This medicinal product is subject to additional monitoring in Australia due to provisional approval. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at
https://www.tga.gov.au/safety/reporting-problems.

*Individuals who had received one or more doses of SARS-CoV-2 vaccine were excluded from the trial. The efficacy of remdesivir is unclear in individuals who are up-to-date with vaccination or partially vaccinated.
COVID-19=coronavirus disease 2019; DGI=German Society for Infectious Diseases; ECMO=extracorporeal membrane
oxygenation; IMV=invasive mechanical ventilation; IDSA=Infectious Diseases Society of America; MHLW=Ministry of Health,
Labour and Welfare; NICE=National Institute for Health and Care Excellence; NIH=National Institutes of Health; NIV=noninvasive
ventilation; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.2
References: 1. NIH. COVID-19 Treatment Guidelines. Clinical Management. Available at: https://www.covid19treatmentguidelines. nih.gov/management/clinical-management. Accessed September 2022. 2. NICE. Guideline [NG191]. COVID-19 rapid guideline: Managing COVID-19. Available at: https://files.magicapp.org/guideline/ad8b80e8-96f8-4c43-a2d4-56605b956eb8/ published_guideline_6385-25_0.pdf. Accessed September 2022. 3. IDSA. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-andmanagement/. Accessed September 2022. 4. MHLW. COVID-19 Treatment Guidance. Available at: https://www.mhlw.go.jp/ content/000668291.pdf. Accessed September 2022. 5. DGI. Recommendations for COVID-19 pharmacotherapy. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569361/. Accessed September 2022. 6. National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. Available at: https://files.magicapp. org/guideline/2b25eac4-3862-40a1-892f-f695064e080f/published_ guideline_6326-57_1.pdf. Accessed September 2022.

© Gilead 2023. All rights reserved. Date of preparation: 02/23. Job code: AU-VKY-0095